​
​

Lipella Pharmaceuticals Stock (NASDAQ:LIPO)

ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.39

52W Range

$0.32 - $1.50

50D Avg

$0.43

200D Avg

$0.64

Market Cap

$2.72M

Avg Vol (3M)

$1.11M

Beta

1.46

Div Yield

-

LIPO Company Profile

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Dec 19, 2022

Website

LIPO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 22
Grant Revenues$184.16K

Fiscal year ends in Dec 23 | Currency in USD

LIPO Financial Summary

Dec 23Dec 22Dec 21
Revenue$449.62M$184.16K$259.35K
Operating Income$-4.75B$-2.59M$-1.92M
Net Income$-4.62B$-2.60M$-1.87M
EBITDA$-4.75B$-2.59M$-1.86M
Basic EPS$-769.43$-0.64$-0.33
Diluted EPS$-769.43$-0.64$-0.33

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
SNTISenti Biosciences, Inc.
MNPRMonopar Therapeutics Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
INBXInhibrx Biosciences, Inc.
FENCFennec Pharmaceuticals Inc.
ANEBAnebulo Pharmaceuticals, Inc.
PTIXProtagenic Therapeutics, Inc.
ICCCImmuCell Corporation
CELCCelcuity Inc.
MACKMerrimack Pharmaceuticals, Inc.
ELVNEnliven Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.